Elevation Oncology’s Post

We are excited to welcome Dr. Henry Koon to team Elevation, where he will take on the role of Vice President, Clinical Development. Henry is a physician scientist with over 20 years of experience in medical oncology and drug development. Learn more about our team on the website: https://lnkd.in/eMCtzw4C

Happy 4th of July from team Elevation!

Elevation Oncology today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company and GSK, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab and dostarlimab, respectively. "We are excited to begin evaluating EO-3021 together with ramucirumab, a VEGFR2 inhibitor, and with dostarlimab, a PD-1 inhibitor, in the second- and first-line settings, respectively,” said Valerie Malyvanh Jansen, M.D., Ph.D., Chief Medical Officer of Elevation Oncology. Full release at https://lnkd.in/eMFCWzhu

This Juneteenth, Elevation joins in recognizing freedom, resilience, and the enduring spirit of Black Americans. We stand by equality and freedom for all, committed to building a more inclusive future. #Juneteenth

At Elevation, we believe in equal rights to life, freedom, and happiness, regardless of sexual orientation or gender identity. We celebrate the LGBTQIA community and equality for all. #PrideMonth #Proud #Equality

Elevation is at #BIO2024! Biren Shah, SVP of Business and Corporate Development, is attending the BIO International Convention 2024 in San Diego. "Looking forward to seeing old friends and evaluating new growth opportunities leveraging Elevation's ADC pipeline,” says Biren. https://lnkd.in/dKrXuHVa

Check out a new episode of the Progress, Potential, And Possibilities podcast where our CEO, Joseph Ferra and CSO, David Dornan, PhD, delve into the current landscape of #ADC space and Elevation’s role in advancing new therapies for cancers. “We are leveraging the latest in ADC technology and our expertise in it to build a differentiated pipeline starting with EO3021 and our second program HER3 ADC,” notes Joseph Ferra. Full episode at https://lnkd.in/eJyrWNuB

Happy Memorial Day from team Elevation!

We are excited to welcome Paul A. Orth, PharmD, to team Elevation, where he will take on the role of Senior Director of Regulatory Sciences. Paul brings over 25 years of experience in the pharmaceutical industry, which will be valuable to advancing the company’s pipeline. Learn more about our team on the website: https://lnkd.in/eMCtzw4C